Quest Diagnostics Inc. (DGX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic path...
Quest Diagnostics Inc.'s revenue increased 11.8% year over year, from $9.87B to $11.04B.
Net income increased 13.9% over the same period, from $871.0M to $992.0M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 47% in total.
Total debt decreased by 8.0% to $5.17B.
The debt-to-equity ratio stands at 0.72, indicating a moderate leverage profile.
Operating cash flow grew 41.4% to $1.89B.
Quest Diagnostics Inc. maintains a moderate net profit margin of 9.0%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $2.49B+3.8% | $226.0M | $811.0M | $330.0M | $356.0M | $16.09B | $5.65B | $6.81B |
| Q4 FY2024 | $2.62B+5.3% | $222.0M | $858.0M | $361.0M | $464.0M | $16.15B | $5.62B | $6.78B |
| Q1 FY2025 | $2.65B+1.2% | $220.0M | $863.0M | $346.0M | $314.0M | $15.80B | $5.86B | $6.93B |
| Q2 FY2025 | $2.76B+4.1% | $282.0M | $943.0M | $438.0M | $544.0M | $15.97B | $5.17B | $7.23B |
| Q3 FY2025 | $2.82B+2.0% | $245.0M | $949.0M | $386.0M | $563.0M | $16.20B | $5.17B | $7.26B |
| Q4 FY2025 | $2.81B-0.4% | $245.0M | $910.0M | $386.0M | $465.0M | $16.23B | $5.17B | $7.17B |
| Q1 FY2026 | $2.90B+3.2% | $252.0M | $942.0M | $399.0M | $278.0M | $16.67B | $6.41B | $7.75B |
| Q2 FY2026 | $3.04B+5.1% | $320.0M | $1.03B | $459.0M | $597.0M | $16.94B | $6.40B | $7.90B |
Balance Sheet Summary (Q2 FY2026)
Quest Diagnostics Inc. (DGX) Financial Statements & Revenue History
Quest Diagnostics Inc. (DGX) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry trading at $235.00 with a market capitalization of $26. This page provides 42 historical financial statements for Quest Diagnostics Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Quest Diagnostics Inc. reported revenue of $11.0 billion, representing 11.8% year-over-year growth. The net profit margin of 9.0% indicates moderate profitability. The debt-to-equity ratio of 0.72 reflects moderate leverage.
DGX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Quest Diagnostics Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether DGX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track DGX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Quest Diagnostics Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of DGX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use DGX Financial Data
Investors use Quest Diagnostics Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare DGX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how DGX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View DGX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Quest Diagnostics Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.DGX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.